Hematology
HEME · guidelines, resources & primary literature
Guidelines & Resources
General
- Thrombosis Canada Clinical Guides — Thrombosis Canada
- Oral Antithrombotic Agents Overview — RxFiles
- Warfarin Dosing Nomogram — RxFiles
VTE
- Thrombosis Canada Clinical Guides — Thrombosis Canada
- Pulmonary Vascular Guidelines — CHEST 2021
- Perioperative Anti-thrombotic Management — RxFiles
Anemia
- Iron Preparations and OTC Products — RxFiles
- IDA Guidelines — BC Guidelines 2023
Anemia of CKD
- CKD Non-Dialysis Anemia — BC Renal 2021
- CKD HD Anemia — BC Renal 2021
- CKD PD Anemia — BC Renal 2021
SFLC
- SFLC Ratio in CKD — (*eg. How to adjust SFLC ratio in the context of CKD*)
Primary Literature
VTE
DVT / PE Treatment
- EINSTEIN-PE — Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism — NEJM 2012
- AMPLIFY — Oral Apixaban for the Treatment of Acute Venous Thromboembolism — NEJM 2013
- HOKUSAI-VTE — Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism — NEJM 2013
- COBRRA — Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism — NEJM 2026
Cytopenias
- Syndromes of Thrombotic Microangiopathy — NEJM 2014
To Be Organized
- Hokusai VTE Cancer — Edoxaban vs. Dalteparin for Cancer-Associated VTE — NEJM 2018
- SELECT-D — Rivaroxaban vs. Dalteparin for Cancer-Associated VTE — JCO 2018
- CARAVAGGIO — Apixaban vs. Dalteparin for Cancer-Associated VTE — NEJM 2020